According to the 2023 ADA standards of care in diabetes (12), GLP-1 RAs with demonstrated CV benefit are considered for T2DM patients with established ASCVD or at high risk for ASCVD to reduce the risk of MACE. The gene discussed is GLP1R; the disease is atherosclerosis.